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Antimicrobial stewardshipa b s t r a c t
Background: Antimicrobial resistance (AMR) is presently considered an emergent major global public
health concern and excessive and/or inappropriate use of broad-spectrum antimicrobials contribute to
the development of AMR.
Objective: To evaluate the appropriateness of carbapenems and piperacillin-tazobactam use in a tertiary
care hospital.
Methods: A retrospective, observational, cross-sectional, drug-utilization study was conducted. The study
included all adult hospitalized patients who had received at least one dose of the antimicrobials during
their admission for the period between 1 January 2016 and 31 December 2017. The appropriateness of
antimicrobial therapy was evaluated according to the Infectious Diseases Society of America (IDSA)
guidelines with the consideration of the institutional antibiogram.
Results: Overall, 2731 patients received 5005 courses with one of the antimicrobials, for a total of 5045.9
defined daily doses (DDD) of imipenem-cilastatin, 6492.3 of meropenem and 15,595 of piperacillin-
tazobactam (4.93, 6.34 and 15.24 DDD/100 bed days, respectively). The mean age of the patients who
received either antimicrobial was 55.5 ± 20.3 years, with a 14-day average length of hospital stay.
About half (52%) of the prescriptions were written for patients treated in the medical ward.
Pneumonia (26.6%) and sepsis (24.9%) were the most common indication for the initiation of antimicro-
bial therapy. Of the assessed prescriptions, only 2787 (56.5%) were prescribed appropriately, with 2142
(43.5%) deemed inappropriate. The three most common reasons for inappropriate prescription were: the
spectrum of activity was too broad (44.6%), followed by antimicrobial use without culture request
(32.4%), and failure of suitable antimicrobial de-escalation (19.9%).
Conclusions: The study indicates that the overall rate of inappropriateness was high, emphasizing the
need to develop initiatives to effectively improve broad-spectrum antimicrobial prescribing.
 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction Health Organization, 2017). At present, the World Health Organi-In the last decade, there has been a substantial increase in bac-
terial organisms resistant to multiple antimicrobial drugs (Worldzation (WHO) considers AMR as a significant global public health
crisis (WHO, 2017). Infections caused by resistant bacteria are not
only difficult to treat (Frieri et al., 2017) but also can prolong
patient hospitalization, increase mortality, morbidity, and the cost
of care (Cosgrove, 2006). Excessive antimicrobial use has been
associated with superinfection and also disease associated with
antimicrobial use, for example, Clostridium difficile, both of which
increase morbidity and mortality in hospitalized patients (Dial
et al., 2008, Wenisch et al., 2012). There is no reliable estimation
of AMR cases worldwide, primarily due to inadequate surveil-
lance. Limitations of any surveillance system or AMR research
are those characteristics associated with the assumptions, design,
methodology and data used that influence the findings explana-
N.A Alsaleh et al. Saudi Pharmaceutical Journal 28 (2020) 1492–1498tion and interpretation (World Health Organization, 2018). The
development and implementation of a standard method for esti-
mating AMR would generate a reliable estimate of AMR globally
(Limmathurotsakul et al., 2019). Despite inadequate surveillance,
some evidence suggests that the incidence is much higher in
developing countries (Ayukekbong et al., 2017). By 2050, it is esti-
mated that 10 million people will die annually from AMR-related
infections (O’Neill, 2016). Inappropriate use of broad-spectrum
antimicrobials contributes to the emergence of AMR (Ventola,
2015). Studies have shown that up to 50% of antimicrobial use
in clinical settings were inappropriate (Dellit et al., 2007,
Hecker et al., 2003). Several studies have demonstrated a correla-
tion between antimicrobial use and the emergence of
antimicrobial-resistant organisms in hospital settings (Bell et al.,
2014, Fishman, 2006). Pseudomonas aeruginosa, and extended-
spectrum beta-lactamases (ESBL) producing gram-negative bacte-
ria are often resistant to multiple antimicrobials presenting
healthcare professionals with limited therapeutic options
(Fatima et al., 2012).
Broad-spectrum antimicrobials such as piperacillin-
tazobactam, imipenem-cilastatin, and meropenem have excellent
activity against many gram-positive, anaerobic, and gram-
negative organisms including many multidrug-resistant strains
of Pseudomonas aeruginosa and Enterobacteriaceae species (Perry
and Markham, 1999, Wilson, 2017). These antimicrobials are
often considered the last resort in treating multi-drug-resistant
bacterial infections and have been classified by the WHO as crit-
ically essential antimicrobials since 2005 (WHO, 2016). Evidence
has shown that disproportionate use of piperacillin-tazobactam
has been associated with the isolation of piperacillin-tazobac
tam-resistant Pseudomonas aeruginosa (Harris et al., 2002, Patel
et al., 2008, Sonmezer et al., 2016). Moreover, increased use of
carbapenems has been linked to carbapenem-resistant Enterobac-
teriaceae, Pseudomonas aeruginosa, and Acinetobacter species
(Mladenovic-Antic et al., 2016, WHO, 2016). The studies have
shown that the rates of carbapenem-resistant Pseudomonas aerug-
inosa, Acinetobacter baumannii, and ESBL-producing Enterobacteri-
aceae are generally high in Saudi Arabian hospital settings
(Zowawi, 2016, Yezli et al., 2014).
Strategies to reduce inappropriate utilization of broad-
spectrum antimicrobials can minimize the emergence of AMR
(Drew, 2009). Studying antimicrobial utilization can assist in
developing strategies to improve the local prescribing practice
for antimicrobials, help tailor evidence-based antimicrobial pre-
scribing, develop antimicrobial prescribing policies and augment
antimicrobial stewardship (AMS) program to control AMR (WHO,
2003). Limited information is currently available in the literature
about carbapenems and piperacillin-tazobactam prescribing in
Saudi Arabia. Previous studies have either included hospitalized
patients in specific departments (Balkhy et al., 2018, Huwait
et al., 2019, Youssif et al., 2018) or focused in narrow patient pop-
ulation (Balkhy et al., 2019). The aim of this study was to assess the
appropriateness of carbapenems (imipenem-cilastatin or merope-
nem) and piperacillin-tazobactam prescribing in Saudi adult hospi-
talized patients including all hospital departments and to identify
reasons, if any, for their inappropriate use.2. Methods
2.1. Ethical approval
Ethical approval was obtained from the Institutional Review
Board, King Saud University College of Medicine (IRB number:
E18-2869).14932.2. Study design and setting
A retrospective, observational, cross-sectional, drug-utilisation
study was conducted in an 1100-bed tertiary care teaching hospi-
tal. The study included all adult hospitalized patients aged 18 years
and older who had received at least one dose of imipenem-
cilastatin, meropenem, or piperacillin-tazobactam during their
inpatient or emergency room admission for the period between 1
January 2016 and 31 December 2017. All neonates, pediatric or
any adult patient who received the studied antimicrobials in home
healthcare settings were excluded from the study. During the
study period, there was no antimicrobial stewardship program in
place.
2.3. Data collection
Data were retrieved from the hospital electronic medical
records (EMRs) and exported to an Excel spreadsheet. The
retrieved data included: patient demographics; indication for
imipenem-cilastatin, meropenem or piperacillin-tazobactam; the
use and duration of antimicrobial therapy; culture and sensitivity
results if available; antimicrobial prescriber specialty and all
antimicrobials prescribed during the patient’s admission.
2.4. Definitions and classifications of antimicrobial prescribing
Antimicrobial therapy was categorized according to the type of
therapy into three main categories: empirical, targeted and pro-
phylactic. Empirical antimicrobial therapy was defined as antimi-
crobials prescribed for a patient suspected to have an infection of
unknown pathogen(s) before the availability of culture and suscep-
tibility results. Targeted antimicrobial therapy was defined as
antimicrobial therapy prescribed for a patient with identified
infection documented in culture and sensitivity results. Prophylac-
tic antimicrobial therapy was defined as antimicrobial therapy pre-
scribed for a patient to prevent an infection or for a patient
undergoing a surgical procedure to avoid surgical site infection
(Leekha et al., 2011). In addition to the number of prescriptions,
the total defined daily doses (DDD) antimicrobial utilization metric
was used to report the antimicrobial use (World Health
Organization, 2020).
2.5. Assessment of antimicrobial appropriateness
The appropriateness of antimicrobial therapy was evaluated
according to IDSA guidelines (IDSA, 2018) with the consideration
of the institutional antibiogram and microbiological findings for
each patient. If the indication of antimicrobial use was empiric
therapy, all cases were reviewed to identify if a microbiology cul-
ture had been requested. If a microbiology culture had been
requested, each case was reviewed for the follow-up of antimicro-
bial therapy (continuation, discontinuation, escalation or de-
escalation) based on reported results. If the indication for treat-
ment was targeted therapy and the antimicrobial was not used ini-
tially as empiric therapy, culture and susceptibility results were
reviewed to check whether the targeted therapy was in accord
with the susceptibility data and the organism was not susceptible
to a narrow-spectrum antimicrobial. Some patients had more than
one admission during the study period. In addition, some patients
may have been prescribed more than one antimicrobial or the
same antimicrobial but at different times during the same admis-
sion period. Each antimicrobial prescription was assessed indepen-
dently, according to its appropriateness. Some patients died or
were discharged before the culture results were obtained. In such
cases, the result was categorized under patient died before the cul-
ture results and was excluded from the analysis.
Table 1
Demographic characteristics of all adult patients prescribed
imipenem-cilastatin, meropenem, or piperacillin-tazobac-
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Reasons for inappropriateness were defined after determining
the appropriateness criteria. Table S1 illustrates the definition of
each reason for inappropriateness of antimicrobial therapy. Some
antimicrobial prescriptions had more than one reason for
inappropriateness.Female 1342 (49.1%)
Age (years) Mean ± SD 55.5 ± 20.3
Length of stay Median (range) 14 (1–3185)
Allergy status:
Documented drug allergy 91 (3.3%)
Documented antimicrobial allergy 48 (1.8%)
Co-morbidities:
Diabetes mellitus 1079 (39.5%)
Cardiovascular disease 702 (25.7%)
Hypertension 767 (28.1%)
Respiratory disease 355 (13%)
Dyslipidaemia 526 (19.3%)
Psychiatric disorder 226 (8.3%)
Musculoskeletal disorder 220 (8.1%)
Haematological disorder 359 (13.1%)
Gastrointestinal disease 232 (8.5%)
Liver disease 154 (5.6%)
Neurological disorders 303 (11.1%)
Thyroid disorder 178 (6.5%)2.7. Statistical analysis
The Shapiro-Wilk test of normality was carried out on all data to
verify the fit of the data to a normal distribution. Categorical vari-
ables were expressed as frequencies and percentages, while con-
tinuous variables were expressed as means, standard deviation
(SD), median, and range where appropriate. To assess whether
there was an association between independent factors and inap-
propriate antimicrobial prescribing we subtracted the percentage
with inappropriate prescribing in the reference category from the
percentage in the exposed category to obtain the percentage risk
difference. Confidence intervals were calculated using the normal
approximation to the binomial distribution. All statistical analyses
were performed with IBM SPSS Statistics for Windows, version
24.0 (Armonk, NY: IBM Corp, 2016).Kidney disease 365 (13.4%)
Cancer 510 (18.7%)
Vitamin D deficiency 215 (7.9%)
Table 2










DDD per 100 bed days 4.93 6.34 15.24
Total courses (n) 776 1021 3208
Type of prescriptions
Empiric 476 (61.3%) 708 (69.3%) 2922 (91.1%)
Targeted 294 (38%) 292 (28.6%) 171 (5.3%)
Prophylaxis 6 (0.7%) 21 (2.1%) 115 (3.6%)
Duration of treatment (days), 7 (1–53) 7 (1–64) 7 (1–48)3. Results
3.1. Patient demographics
A total of 2871 patients received 5250 courses of antimicrobial
treatment with at least one of the studied broad-spectrum antimi-
crobials during 3671 patient admissions over a two-year period.
Six hundred and sixty-eight patients were prescribed two courses
of antimicrobials, and 1219 patients were prescribed more than
two courses. One hundred and forty patients who received 245
(4.7%) courses of antimicrobials during 167 visits were excluded
from the assessment due to a lack of documentation. The mean
age of the patients was 55.5 years (SD = ±20.25, range 18 - 108
years), and 1389 (50.9%) were male. During the study period, 377
(13.8%) patients died, and 885 (32.4%) had surgery. The demo-
graphic characteristics of the patients are summarized in Table 1.Median (range)3.2. Antimicrobial use
Overall, on 4106 (82%) occasions antimicrobials were pre-
scribed as empiric therapy, 757 (15.2%) were as targeted therapy
after a pathogen had been identified in a clinical specimen, and
142 (2.8%) were as prophylactic therapy. Table 2 shows the types
of prescriptions and the duration of treatment for imipenem-
cilastatin, meropenem and piperacillin-tazobactam.
The highest proportion of prescriptions were written for the
patients treated in a medical ward (52%) followed by surgical
wards (23.4%), intensive care unit (ICU, 15.3%), and emergency
department (ED, 2.2%). Pneumonia (26.6%) was the most common
indication for initiation of antimicrobial therapy, followed by sep-
sis (24.9%), urinary tract infections (17.3%), skin and soft tissue
infections (14.8%), intra-abdominal infections (8.6%) and febrile
neutropenia (4%). Table 3 summarizes the main indications for
imipenem-cilastatin, meropenem and piperacillin-tazobactam.
Medical residents prescribed the majority of antimicrobial therapy
(64.7%), followed by internal medicine specialists (17%) and ICU
specialist (11%). Culture and sensitivity tests were ordered on
3408 (68%) occasions before prescribing antimicrobials; 2651
(52.9%) were before initiating empiric antimicrobial therapy.14943.3. Appropriateness of antimicrobial therapy
Overall, 4929 (98.5%) of the prescribed antimicrobials were
assessed for their appropriateness of prescribing. A small number
(76, 1.5%) of the prescribed antimicrobials could not be assessed
as some patients were either discharged or died before culture
results became available. The results showed that only 2787
(56.5%) of antimicrobial orders were prescribed appropriately,
with 2142 (43.5%) inappropriate. An empirical initiation of
piperacillin-tazobactam was only appropriate in 52.3% of the total
piperacillin-tazobactam prescriptions. Almost all carbapenems and
piperacillin-tazobactam prescribed as prophylactic therapy were
inappropriate. Table 4 illustrates the appropriateness of
imipenem-cilastatin, meropenem and piperacillin-tazobactam
prescriptions.
The most common reasons for inappropriate use of antimicro-
bials were: spectrum of activity was too broad (44.6%), antimicro-
bial use without culture request (32.4%), failure of suitable
antimicrobial de-escalation (19.9%), continuation of antimicrobial
prescribing despite microbiology results indicating resistance
(2%), and known allergy to the prescribed antimicrobial (1.1%).
Table 3







Febrile neutropenia 199 21 (2.7%) 27 (2.6%) 151 (4.7%)
Gynaecological infection 5 0 (0%) 0 (0%) 5 (0.2%)
Intra-abdominal infection 431 54 (7%) 53 (5.2%) 324 (10.1%)
Meningitis 8 0 (0%) 3 (0.2%) 5 (0.2%)
Osteomyelitis 25 5 (0.6%) 9 (0.9%) 11 (0.3%)
Pneumonia 1333 122 (15.7%) 203 (19.9%) 1008 (31.4%)
Sepsis 1248 257 (33.1%) 359 (35.2%) 632 (19.7%)
Skin and soft tissue infection 743 130 (16.8%) 130 (12.7%) 483 (15.1%)
Urinary tract infection 864 181 (23.3%) 213 (20.9%) 470 (14.7%)
aOther 7 0 (0%) 3 (0.3%) 4 (0.1%)
Prophylaxis
Surgical prophylaxis 102 3 (0.4%) 8 (0.8%) 91 (2.8%)
bOther prophylaxis 40 3 (0.4%) 13 (1.3%) 24 (0.7%)
a Other includes endocarditis and acute otitis externa.
b Other prophylaxis includes trauma, burn and bite.
N.A Alsaleh et al. Saudi Pharmaceutical Journal 28 (2020) 1492–1498As some antimicrobial prescriptions had more than one reason for
inappropriateness, the total number for the identified reasons were
2870. Fig. 1 outlines the reason why antimicrobials were inappro-
priate for of imipenem-cilastatin, meropenem and piperacillin-
tazobactam.
There were no significant differences in the incidence of appro-
priate antimicrobial prescribing based on age, gender and patient
location (ICU versus non-ICU). Patients with two or more co-
morbidities were more likely to be prescribed inappropriate
antimicrobial than patients with no co-morbidities (51.2% versus
42.9%; risk difference 8.3%; 95% CI, 2.8% to 13.8%) and (51.7% ver-
sus 42.9%; risk difference 8.8%; 95% CI, 4.5% to 13.1%). Prescriptions
that were for targeted therapy were less likely to be inappropriate
than prescriptions that were for empiric therapy (22.5% versus
45.4%; risk difference –22.9%; 95% CI, 26.3%, to 19.5%). Prescrip-
tions that were for prophylaxis therapy were more likely to be
inappropriate than prescriptions that were for empiric therapy
(99.3% versus 45.4%; risk difference 53.9%; 95% CI, 51.8% to 56%).
Table 5 shows the characteristics of patients prescribed both
appropriate and inappropriate antimicrobials. Table 6 illustrates
the appropriateness of antimicrobials according to the indication.4. Discussion
This study provides important insights into the current pre-
scribing practices of three broad-spectrum antimicrobials at a ter-Table 4
Appropriateness of imipenem-cilastatin, meropenem and piperacillin-tazobactam
prescriptions.




























1495tiary hospital within Saudi Arabia. Inappropriate use of
antimicrobials is a common practice in hospital settings. Epidemi-
ological studies have shown that there is an association between
antimicrobial consumption and the emergence and spreading of
bacteria resistance (Bell et al., 2014, Fishman, 2006). Drug utiliza-
tion studies are useful in identifying current practice in hospital
settings (WHO, 2003). The results of this study may be useful in
assisting healthcare providers to improve the current practice
and, therefore, reduce the emergence of resistant bacteria.
The consumption of piperacillin/tazobactam in this study was
15.24 DDDs per 100 bed days which was similar to previously
reported Saudi (13.4 DDDs per 100 bed days; Balkhy et al., 2018),
Australian & New Zealand studies (12.4 (13.4 DDDs per 100 bed
days; Dulhunty et al., 2011) and was higher than reported in an
Indian study (3.04 DDDs per 100 bed days; Ray and Datta, 2018).
Unlike piperacillin/tazobactam, the consumption of carbapenem
was 11.27 DDDs per 100 bed days which was less than previously
reported in local (25.6 DDDs per 100 bed days; Balkhy et al., 2018)
and international studies (67.6 DDDs per 100 bed days, Ray and
Datta, 2018 and 25.7 DDDs per 100 bed days, Dulhunty et al.,
2011).
In this study, broad-spectrum antimicrobials were commonly
prescribed in the internal medicine wards. The most common indi-
cation for prescribing carbapenems and piperacillin-tazobactam
was pneumonia, followed by sepsis. A study conducted by Youssif
et al., found that the most common indication for prescribing car-
bapenems and piperacillin-tazobactam was skin and soft tissue
infections, followed by intra-abdominal infections (Youssif et al.,
2018). Reported differences may be due to the inclusion of surgical
floors in the later study.
In this study, we have reported the results as the proportion of
inappropriate prescriptions instead of the proportion of patients
for the reason that 65.7% of the patients received more than one
antimicrobial prescription during the evaluation period. The study
found that the overall appropriate use of the three broad-spectrum
antimicrobials was 56.5%. Most antimicrobials were prescribed for
empirical indication (82%) and only 15.2% were post-culture
results; the rate of appropriateness of empiric therapy was signif-
icantly lower than targeted therapy. Empiric indication of
piperacillin-tazobactam was appropriate in 52.3% of the empiric
courses. The current results are similar to the study by Khan
et al. in evaluating piperacillin-tazobactam use in an adult popula-
tion, which found that piperacillin-tazobactam was appropriately
initiated in 57% of courses (Khan et al., 2012). In contrast, the
results of the current study differ from other studies, where it
was calculated that piperacillin-tazobactam was appropriately ini-
tiated on 71.5–93% occasions (Janowski et al., 2016, Raveh et al.,
Fig. 1. Reasons for the inappropriate prescribing for imipenem-cilastatin, meropenem and piperacillin-tazobactam.
Table 5





























































































Prophylaxis 1/142 (0.7%) 141/142
(99.3%)
53.9% (51.8 to 56)
* Values in bold represent data where there is a significant difference with
p  0.05.
Table 6







Treatment (empiric and targeted)
Febrile neutropenia 63/199 (31.7%) 134/199
(67.3%)
2/199 (1%)






Meningitis 3/8 (37.5%) 5/8 (62.5%) 0/8 (0%)


























aOther 4/7 (57.1%) 3/7 (42.9%) 0/7 (0%)
Prophylaxis
Surgical prophylaxis 0/102 (0%) 102/102
(100%)
0/102 (0%)
bOther prophylaxis 1/40 (2.5%) 39/40 (97.5%) 0/40 (0%)
a Other includes endocarditis and acute otitis externa.
b Other prophylaxis includes trauma, burn and bite.
N.A Alsaleh et al. Saudi Pharmaceutical Journal 28 (2020) 1492–14982006, Shah and Ryzner, 2013, Zeenny et al., 2014). The differences
may be due to the variation in indication between pediatric versus
adult populations, variations in prescriber education or the status
of AMS in each hospital. The rate of appropriateness of empiric
indication of meropenem and imipenem was 57.9% and 63.5%,1496respectively. A higher rate of imipenem appropriateness was
demonstrated in another study using different methodology
(Kabbara et al., 2015). Overall, the low rate of appropriateness
observed in this studymay have been for several reasons, including
a lack of institutional guidelines and prescriber education.
The most common diagnosis in the category of inappropriate-
ness was pneumonia and sepsis. In sepsis, a delay in antimicrobial
prescribing is associated with increased mortality (Levy et al.,
2018). The initial step in sepsis management is identification of
patients with sepsis, which can be clinically challenging. Sepsis
diagnosis is extremely subjective and identification can be com-
plex, particularly in the early stages when presenting symptoms
are non-specific and test results are pending. This means that a
prescriber must make early decisions regarding antimicrobials
usage (Vincent, 2016). In this period of uncertainty, prescribers
need to act, balancing the risks of failing to treat sepsis versus over-
prescribing, and the risk of increasing AMR. To avoid potential con-
sequences from inappropriate antimicrobial prescribing, including
AMR and infections such as Clostridium difficile infection, AMS
strategies, including guidelines and de-escalation protocols, should
be implemented (Davey et al., 2017).
N.A Alsaleh et al. Saudi Pharmaceutical Journal 28 (2020) 1492–1498The most common reason given for the assessment of inappro-
priateness was that the spectrum of activity was too broad (44.6%).
The high percentage of inappropriate initial selection of these
broad-spectrum antimicrobials is concerning. Such overprescribing
is associated with an increased risk of AMR, adverse effects, oppor-
tunistic infections and increased healthcare costs (Tamma et al.,
2017). We, therefore, propose the need for AMS. Possible AMS
strategies include guideline implementation and staff education
(Davey et al., 2017).
In terms of microbiological tests, culture tests were requested
to guide therapy in 52.9% of prescriptions. Of these prescriptions,
failure of de-escalation, although warranted, was shown in 19.9%
of cases. The failure of de-escalation may be due to the reluctance
of prescribers to make modifications to a clinically unwell patient’s
therapy or the tendency toward continuation of a therapy that
appears to be effective (Paterson, 2006). Nevertheless, this rate
and duration of therapy was concerning and is considered a focus
area for a future intervention in antimicrobial prescribing practice.
Analysis of antimicrobial appropriateness for pre-defined sub-
groups of patients and prescriptions showed that patients who
had a higher number of co-morbidities were more likely to be pre-
scribed inappropriate antimicrobials than those who had fewer or
no co-morbidities. We assume that for these patients, prescribers
might prescribe broad-spectrum antimicrobials inappropriately
in order to prevent the decompensation of co-morbidities related
to sepsis. In addition, we found a significant association between
empiric treatment and inappropriate antimicrobial prescribing.
This implies that the empiric use of carbapenems and
piperacillin-tazobactam was significantly associated with their
inappropriate use.
The hospital does not currently have treatment guidelines
regarding appropriate indications for the use of carbapenems and
piperacillin-tazobactam. Establishing and implementing antimi-
crobial guidelines and in parallel educating and supporting pre-
scribers in their adoption would be a feasible intervention that
has been shown to be a cost-effective moderate impact activity
(Robson et al., 2018). Another antimicrobial utilization evaluation
could be conducted after these interventions have been imple-
mented to evaluate their impact and to additionally direct AMS
activities.
4.1. Strengths and limitations
To the best of our knowledge, this is the first study in the Gulf
countries that has evaluated the appropriateness of the three
broad-spectrum antimicrobials, including all hospitalized adult
patients in tertiary care hospitals. The strength of the study was
the large sample size. The study had several limitations. The inher-
ent limitation lies in employing a retrospective study design, even
though this is a common and acceptable method for evaluating
appropriateness of antimicrobial therapy in hospital settings. In
addition, as the assessment did not occur at the time of prescribing,
the degree of accuracy of interpretations of information extracted
from the hospital electronic database in the assessment of pre-
scriptions relies on how much information had been recorded.
However, the electronic chart captured comprehensive informa-
tion on the course during hospitalization and physician notes and
reports on microbiological findings. A further limitation is that the
study was conducted in a single academic tertiary care hospital,
which may limit the generalizability of the study. It should be
noted, though, that all hospital wards were included, which
assisted representative results being recorded across a range of dis-
ciplines. Finally, a lack of local guidelines prevailed. Hospital
antibiograms were considered in the evaluation, involving the
use of international guidelines. Therefore, the results can be com-
pared with those in the literature.14975. Conclusion
This study has provided important insights into the use and
appropriateness of broad-spectrum antimicrobials. The study
shows that there is considerable inappropriate prescribing of
broad-spectrum antimicrobials. Our study implies that AMS is
needed to optimize their use in hospital settings to reduce the
emergence of resistant organisms and to optimize patient safety
and outcomes. Future research is needed to further explore factors
associated with inappropriate antimicrobial prescribing practices
as well as the impact of interventions on improving antimicrobial
prescribing.
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